Gladstone Institutional Advisory LLC Acquires Shares of 9,859 TransMedics Group, Inc. (NASDAQ:TMDX)

Gladstone Institutional Advisory LLC bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 9,859 shares of the company’s stock, valued at approximately $615,000.

A number of other large investors also recently modified their holdings of the company. Hager Investment Management Services LLC acquired a new position in TransMedics Group during the fourth quarter worth $33,000. Sachetta LLC bought a new stake in shares of TransMedics Group during the fourth quarter worth about $40,000. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after acquiring an additional 312 shares during the last quarter. National Bank of Canada FI lifted its position in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after acquiring an additional 262 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in TransMedics Group by 187.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 485 shares of the company’s stock valued at $76,000 after purchasing an additional 316 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TMDX has been the topic of a number of recent research reports. Needham & Company LLC restated a “hold” rating on shares of TransMedics Group in a report on Wednesday, February 5th. JPMorgan Chase & Co. restated a “neutral” rating and set a $75.00 price objective (down from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Piper Sandler reduced their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Canaccord Genuity Group dropped their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, TD Cowen reduced their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, TransMedics Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $122.70.

TransMedics Group Price Performance

TransMedics Group stock opened at $72.18 on Friday. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The business’s 50 day simple moving average is $65.79 and its 200 day simple moving average is $107.46. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a market cap of $2.42 billion, a price-to-earnings ratio of 76.79 and a beta of 2.12.

Insider Activity

In related news, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $1,800,835.20. The trade was a 4.94 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.